Core Viewpoint - Selay is redefining the dietary supplement industry with a focus on personalized health solutions, combining natural ingredients with scientific innovation to cater to diverse consumer needs [1][5][7] Group 1: Product Philosophy - Selay emphasizes the importance of pure, natural ingredients sourced from plants and animals, ensuring high quality through rigorous selection processes [3] - The brand utilizes organic materials from local German farms and high-purity fish oil from Norway, achieving an Omega-3 content of 95% with minimal heavy metal residues [3] Group 2: Targeted Product Lines - Selay offers personalized product lines for various demographics, including blood sugar balance capsules for the elderly, hormone-regulating drinks for women, vitality supplements for men, and growth drinks for children [5] - Each product is designed to address specific health needs, such as cardiovascular health, metabolic balance, and developmental support for children [5] Group 3: Consumer Impact - The "Selay Arginine Capsule" exemplifies the brand's approach, combining ingredients like maca, arginine, oyster peptides, and zinc to significantly enhance physical strength and energy levels [7] - Selay aims to provide health solutions that resonate with different lifestyles, from busy professionals to health-conscious homemakers, ensuring that everyone can find their ideal health answer [7] Group 4: Future Outlook - The company is committed to ongoing research and innovation, with plans to expand its product line and offer more precise and effective nutritional solutions [7] - Selay envisions a future where health is easily accessible, promoting a lifestyle that harmonizes scientific advancements with natural wellness [7]

编辑｜海若镜 在看似被生长激素"垄断"的儿童增高市场，后来者还有没有机会？ 经历过去10多年的市场渗透，提到能帮助小孩子长高的"外力作用"，除了补钙、运动和睡眠外，打生长激素已逐渐成为家长们的下意识反应。 只是，生长激素终究只是有明确适用人群限制的药品，在大众"追高"的时代，这显然有些"不够用"了。 针对非矮身材儿童的"追高"需求，近两年的消费医疗市场上，其实已逐渐跑出几个新玩家，36氪近期接触到的阿基孚就是其中之一。阿基孚是 美国品牌agebox旗下的产品，核心产品是一款"IGF-1生长因子增敏剂"。2022年底进入中国市场至今，儿童用户数已超过4万人，用户综合复购 率达到70%。中国区团队规模也从几十人快速扩张至如今的几百人。 文｜胡香赟 为什么一款用于增高的膳食补充剂也可以成为"爆品"？最近，agebox亚太区负责人Ryan Luo和产品专家Ben Wang一起向36氪分享了他们的经 验。 Ryan Luo提到，以中国市场来讨论，首先有必要对现在的"增高"市场进行区分。目前，"增高"市场基本是以生长激素为基础统计的，只针对身 高低于P3（100名孩子中最矮的3个，对应男、女性成年预测身高为161.3cm ...

Core Viewpoint - Company reported a significant decline in Q1 2025 revenue and net profit, attributed to high base effects and weak demand, prompting a need for strategic adjustments in product and channel management [1][2][3] Financial Performance - Q1 2025 revenue reached 1.79 billion yuan, down 32.3% year-on-year; net profit attributable to shareholders was 450 million yuan, down 37.4%; and net profit excluding non-recurring items was 410 million yuan, down 42.4% [1] - The main brand "汤臣倍健" generated 983 million yuan in revenue, a decrease of 36.37% year-on-year; "健力多" revenue was 201 million yuan, down 46.15%; and Life-Space domestic products brought in 77 million yuan, down 36.19% [1] - International business, represented by LSG, achieved revenue of 244 million yuan, up 5.94% year-on-year, indicating relative stability [1] - Offline channel revenue was 988 million yuan, down 42.62%; online channel revenue was 766 million yuan, down 15.78%, with offline sales significantly impacted by reduced foot traffic and high base effects [1] Cost Management - Q1 2025 gross margin was 68.66%, a decrease of 1.24 percentage points, primarily due to a higher proportion of low-margin products and increased fixed costs from declining revenue [2] - Sales expense ratio was 30.29%, down 0.91 percentage points, reflecting effective cost control measures [2] - Management expense ratio increased to 5.77%, up 1.02 percentage points, due to the decline in revenue [2] - Overall, the net profit margin for Q1 2025 was 26.04%, down 1.13 percentage points year-on-year [2] Strategic Initiatives - In Q2, the company plans to launch new products aimed at revitalizing offline channel sales, including new formats for vitamins and probiotics, and targeting essential consumer groups [3] - The company will conduct offline product launch events to enhance brand visibility and consumer engagement [3] - Profit forecasts for 2025-2027 have been revised downwards due to ongoing weak demand, with projected net profits of 791 million yuan, 921 million yuan, and 1.024 billion yuan, representing reductions of 13%, 17%, and 19% respectively [3] - The company maintains a "buy" rating, emphasizing its leadership position in the dietary supplement industry and the sector's growth potential [3]

2025 年 4 月 27 日 公司研究 业绩继续承压，关注新品上市进展 ——汤臣倍健（300146.SZ）2025 年一季报点评 要点 事件：汤臣倍健 25Q1 实现营业收入 17.9 亿元，同比-32.3%；归母净利润 4.5 亿元，同比-37.4%；扣非归母净利润 4.1 亿元，同比-42.4%。 高基数及需求疲软，致收入承压。1）分产品看：25Q1 主品牌"汤臣倍健"实 现营收 9.83 亿元，同比-36.37%；关节护理品牌"健力多"实现营收 2.01 亿元， 同比-46.15%；Life-Space 国内产品实现营收 0.77 亿元，同比-36.19% 。主品 牌及健力多营收下滑幅度较大，主要系去年同期基数较高，且两大核心单品迭代 升级后终端销售不及预期所致。境外业务方面，LSG 实现营收 2.44 亿元，同比 +5.94%（澳元口径营收 0.54 亿澳元，同比+10.14%），表现相对稳健 。2）分 渠道看：线下渠道实现收入 9.88 亿元，同比-42.62%；线上渠道实现收入 7.66 亿元，同比-15.78% 。线下渠道收入大幅下降，主要受药店渠道客流及 VDS 销 售规模持续下行、去年同期 ...